Seelos therapeutics announces closing of public offering

New york , dec. 1, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 1,781,934 shares of its common stock, pre-funded warrants to purchase up to 2,422,612 shares of its common stock and accompanying common warrants to purchase up to 4,204,546 shares of its common stock. each share of common stock and accompanying common warrant to purchase one share of common stock were sold at a combined price to the public of $1.32 per share of common stock and accompanying common warrant and each pre-funded warrant and accompanying common warrant to purchase one share of common stock were sold at a combined price to the public of $1.319 per pre-funded warrant and accompanying common warrant.
SEEL Ratings Summary
SEEL Quant Ranking